Connecticut

Connecticut

44,327
Registered Patient Population
1.24%
of Total Population Represented by Patients
17
Total Medical Retail Locations Currently in Operation
4,925 : 1
Patients : Retail

Medical cannabis is legal to qualified patients in Connecticut. Patients and caregivers registered with the Department of Consumer Protection may purchase medical cannabis from state-licensed dispensaries, but no personal cultivation is allowed. Patients and caregivers may possess up to 2.5 ounces of cannabis. Patients report feeling irritated about inconsistent product availability at dispensaries or feel prices too expensive to be a medical cannabis patient as taxes on medical cannabis are too high. Connecticut does not recognize out of state medical cannabis cards

Patient Rights and Civil Protection 74/100   
Arrest Protection 40/40
Affirmative Defense 13/15
Parental Rights Protections 0/10
DUI Protections 0/5
Employment Protections 5/5
Explicit Privacy Standards 7/7
Housing Protections 5/5
Does Not Create New Criminal Penalties for Patients 4/5
Organ Transplants 0/5
Reciprocity 0/3
Access to Medicine 68/100   
Allows Distribution Programs 28/40
– Allows Access to Dried Flowers 15/15
– Allows Delivery 0/5
– No Sales Tax or Reasonable Sales Tax 4/5
– Allows for a Reasonable Number of Dispensaries 4/5
– Does Not Require Vertical Integration 2/2
– Ownership/Employment Restrictions 1/2
– Provisions for Labor Standards 0/2
– Environmental Impact Regulations 0/2
– Choice of Dispensary Without Restrictions 2/2
Noncommercial Cultivation 0/20
– Personal Cultivation 0/15
– Collective Gardening 0/5
Explicit Right to Edibles/Concentrates/Other Forms 10/10
Does not Impose Bans or Limits on THC 10/10
Does not Impose Bans on CBD 10/10
Local Bans/Zoning 10/10
Comprehensive Qualifying Conditions 46/50
Adding New Conditions 10/10
– Law/Regulations Allow for New Conditions 5/5
– System Works for Adding New Conditions 5/5
Reasonable Access for Minors 8/10
Reasonable Caregiver Background Checks 4/4
Number of Caregivers 2/2
Patient/Practitioner-Focused Task Force or Advisory Board 0/2
Reasonable Fees (Patients and Caregivers) 7/10
Allows Multiple-Year Registrations 0/2
Reasonable Physician Requirements 4/5
Does Not Classify Cannabis as a Medicine of Last Resort 5/5
Functionality 77/100   
Patients Able to Access Medicine at Dispensaries or by Cultivation 45/50
No Significant Administrative or Supply Problems 14/15
Patients Can Receive Legal Protections Within Reasonable Time Frame of Doctor's Recommendation 8/10
Reasonable Possession Limits 4/5
Reasonable Purchase Limits 3/5
Allows Patients to Medicate where They Choose 3/5
Covered by Insurance/State Health Aid 0/3
Financial Hardship (Fee Waivers/Discount Medicine) 0/7
Consumer Safety and Provider Requirements 77/100   
Dispensing 23/25
Staff Training 5/5
Standard Operating Procedures 5/5
– Facility Sanitary Conditions 1.25/1.25
– Storage Protocols 1.25/1.25
– Reasonable Security Protocols 1.25/1.25
– Inventory Control 1.25/1.25
Recall Protocol and Adverse Event Reporting 5/5
Product Labeling 2.67/5
– Product Contents, Including Source Material Identification 1.67/1.67
– Allergens 0/1.67
– Potency/Compound Identification 1/1.67
Required Testing 5/5
– Active Compound Identification 1.67/1.67
– Contaminants 1.67/1.67
– Potency 1.67/1.67
Grow/Cultivation 19/25
Staff Training 0/5
Standard Operating Procedures 4/5
– Facility and Equipment Sanitary Conditions 0.71/0.71
– Workforce Safety Protocols 0/0.71
– Storage Protocols (Short-Term and Long-Term Storage) 0.71/0.71
– Reasonable Security Protocols 0.71/0.71
– Batch and Lot Tracking 0.71/0.71
– Disposal/Waste 0/0.71
– Water Management 0/0.71
Pesticide Guidance 5/5
– Pesticide Guidance 2.5/2.5
– Pesticide Labeling 2.5/2.5
Required Testing 5/5
– Active Ingredient Identification 1.25/1.25
– Contaminants 1.25/1.25
– Potency 1.25/1.25
– Sample Retention 1.25/1.25
Recall Protocol and Adverse Event Reporting 5/5
Manufacturing 18/25
Staff Training 0/5
Standard Operating Procedures 4/5
– Facility and Equipment Sanitary Conditions 0/1
– Workforce Safety Protocols 1/1
– Storage Protocols 1/1
– Reasonable Security Protocols 1/1
– Batch and Lot Tracking 1/1
Product Labeling 5/5
– Product Contents, Including Source Material Identification 1.67/1.67
– Allergens 1.67/1.67
– Potency and Compound Information 1.67/1.67
Required Testing 4/5
– Active Ingredient Identification 1/1
– Contaminants 1/1
– Potency 1/1
– Shelf Life Testing 0/1
– Sample Retention 1/1
Recall Protocol and Adverse Event Reporting 5/5
Laboratory Operations 17.49/25
Staff Training 5/5
Method Validation in Accordance with AHP Guidelines 0/5
Result Reporting 5/5
Independent or Third Party 5/5
Standard Operating Procedures and Protocols 2.49/5
– Equipment and Instrument Calibration 0/0.83
– Sample Tracking 0.83/0.83
– Facility and Equipment Sanitary Conditions 0.83/0.83
– Disposal/Waste 0/0.83
– Storage Protocols 0.83/0.83
– Workforce Safety Protocols 0/0.83
Covid Response 14/20   
Delivery Available? 2/6
Curbside Pickup Available? 2/2
Medical Cannabis Essential? 7/7
Telemedicine Available? 3/5
Excerpted from ASA's 2020 State of the States Report.
page icon

Becoming a Patient in Connecticut

page icon

Recommending Cannabis in Connecticut

page icon

Connecticut Advocacy

page icon

History Of Medical Cannabis In Connecticut

page icon

Policy Recommendations Connecticut